The paradigm-shifting therapeutics in NPC, including alleviating viral infection, inactivating Treg-mediated suppression and expanding TLS-associated B cells within the TME, might also be feasible in HPV+ HNSCC to synergistically promote PD-1/PD-L1 efficacy. This evidence concerns the gene CD274 and head and neck squamous cell carcinoma.